Patent US5268358A successfully refreshed from Google Patents.
US5268358A
Expired / Lapsed
US
⏱️ 0.0 years remaining
PDGF receptor blocking peptides
Assignee: COR Therapeutics Inc
•
Filing: 1991-05-06
•
Granted: 1993-12-07
•
Expires: 2011-05-06
Abstract
Abstract Methods and compositions are provided for treating several acute disease states associated with smooth muscle cell proliferation as well as the chronic process of atherogenesis utilizing oligopeptides corresponding to regions of the PDGF receptor protein. The oligopeptides can be used to block PDGF binding and activation for numerous applications, and can serve as immunogens to raise receptor-specific antibodies.
Inventors
- 👤 Larry J. Fretto
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 23:24
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/705; C07K14/71; A; A61; A61K; A61K38/00
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
109 words
A blocking oligopeptide comprising at least about five contiguous amino acids from an oligopeptide of the formula: ##STR6## wherein: X, if present, is hydrogen, amido, acetyl, or additionally includes an amino acid, dipeptide, tripeptide or a polypeptide of up to 50 amino acid residues; Z, if present, is hydroxyl, amido, or additionally includes an amino acid, dipeptide, tripeptide or a polypeptide of up to 50 amino acid residues; the amino contiguous acids are not selected from X or Z, and the blocking oligopeptide has less than about 50 natively associated amino acids, wherein the blocking oligopeptide is capable of specifically binding to platelet derived growth factor and/or its receptor.
Claim 2
Dependent Claim
109 words
A blocking oligopeptide comprising at least about five contiguous amino acids from an oligopeptide of the formula: ##STR6## wherein: X, if present, is hydrogen, amido, acetyl, or additionally includes an amino acid, dipeptide, tripeptide or a polypeptide of up to 50 amino acid residues; Z, if present, is hydroxyl, amido, or additionally includes an amino acid, dipeptide, tripeptide or a polypeptide of up to 50 amino acid residues; the amino contiguous acids are not selected from X or Z, and the blocking oligopeptide has less than about 50 natively associated amino acids, wherein the blocking oligopeptide is capable of specifically binding to platelet derived growth factor and/or its receptor.
Claim 3
Dependent Claim
14 words
A blocking oligopeptide according to claim 1, wherein the blocking oligopeptide is a salt.
Claim 4
Dependent Claim
16 words
A blocking oligopeptide according to claim 1, wherein the carboxy-terminal amino acid is free or amidated.
Claim 5
Dependent Claim
16 words
A blocking oligopeptide according to claim 1, wherein the amino-terminal amino acid is free or acetylated.
Claim 6
Dependent Claim
54 words
A pharmaceutical formulation comprising a blocking oligopeptide according to claims 1, 2, 3, or 4 in combination with a pharmaceutically-acceptable carrier, wherein the blocking oligopeptide is present in an amount sufficient to inhibit smooth muscle cell migration and proliferation by interfering with the binding of platelet-derived growth factor to the platelet-derived growth factor receptor.
References Cited (Backward Citations)
US4845075A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-12-06 | 1997-06-07 | 1997-12-07 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-12-06 | 2001-06-07 | 2001-12-07 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-12-06 | 2005-06-07 | 2005-12-07 | $7700.00 | Window Closed / Lapsed |